i agree - am waiting for things to settle. think is still a good LT outlook with the products they have in development. and as i said, there are definitely some positives from the trial that will hopefully enable them to find the 'market' in RCC for 105. is also good for science/medicine as well - surrogate markers reflecting disease response are invaluable in clinical management - hopefully some of those identified here become clinically validated for routine use....
BNO Price at posting:
54.0¢ Sentiment: None Disclosure: Held
